Tue, Apr 29, 8:14 PM (13 days ago)
Amedisys, Inc. (AMED) filed an amendment to its annual report (Form 10-K/A) for the fiscal year ended December 31, 2024. This amendment primarily includes updates to Part III of the original Form 10-K, focusing on directors, executive officers, and corporate governance. Key highlights include: **Executive Compensation:** - **Richard Ashworth** (CEO): Received a base salary of $1,030,000, a bonus of $1,416,559, and stock awards valued at $5,150,035. - **Scott G. Ginn** (COO, CFO): Received a base salary of $692,135, a bonus of $956,178, and stock awards valued at $1,545,057. - **Nick Muscato** (CSO): Received a base salary of $445,856, a bonus of $541,525, and stock awards valued at $1,515,049. - **Denise Bohnert** (CCO): Received a base salary of $410,154, a bonus of $424,968, and stock awards valued at $515,050. - **Jennifer Griffin** (CLO): Received a base salary of $373,323, a bonus of $250,091, and stock awards valued at $206,001. **Director Compensation:** - Directors received an annual cash retainer of $100,000 and equity awards valued at $154,500. **Strategic Overview:** - Amedisys cared for over 499,000 patients, making more than 10.7 million visits. - Maintained high quality of patient care scores and outperformed industry averages in various metrics. - Achieved significant growth in admissions and average daily census. **Financial Performance:** - Net service revenue increased to $2,348.3 million. - Generated $222 million in cash flow from operations. - Reduced voluntary turnover to 18%. **Future Outlook:** - Pending merger with UnitedHealth Group, subject to regulatory approvals. - Focus on retention and continuity of the management team during the merger process. **Risk Factors:** - Regulatory approvals for the merger. - Integration challenges post-merger. - Market and operational risks. **Financial Condition:** - Strong cash flow and revenue growth. - Strategic investments in high-acuity care and technology. **Market Position:** - Leading position in home health and hospice care. - Strong focus on quality and patient satisfaction. **Changes in Market Position:** - Continued growth in admissions and patient satisfaction scores. - Strategic investments in technology and high-acuity care. **Amendment Details:** - This amendment includes updates to Part III of the original Form 10-K, focusing on directors, executive officers, and corporate governance. - No changes to financial statements or other disclosures.